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ABSTRACT
The Cdk12/CycK complex promotes expression of a
subset of RNA polymerase II genes, including those
of the DNA damage response. CDK12 is among only
nine genes with recurrent somatic mutations in high-
grade serous ovarian carcinoma. However, the influ-
ence of these mutations on the Cdk12/CycK complex
and their link to cancerogenesis remain ill-defined.
Here, we show that most mutations prevent forma-
tion of the Cdk12/CycK complex, rendering the ki-
nase inactive. By examining the mutations within the
Cdk12/CycK structure, we find that they likely pro-
voke structural rearrangements detrimental to Cdk12
activation. Our mRNA expression analysis of the pa-
tient samples containing the CDK12 mutations re-
veals coordinated downregulation of genes critical to
the homologous recombination DNA repair pathway.
Moreover, we establish that the Cdk12/CycK com-
plex occupies these genes and promotes phospho-
rylation of RNA polymerase II at Ser2. Accordingly,
we demonstrate that the mutant Cdk12 proteins fail
to stimulate the faithful DNA double strand break
repair via homologous recombination. Together, we
provide the molecular basis of how mutated CDK12
ceases to function in ovarian carcinoma. We propose
that CDK12 is a tumor suppressor of which the loss-
of-function mutations may elicit defects in multiple
DNA repair pathways, leading to genomic instability
underlying the genesis of the cancer.
INTRODUCTION
Gene transcription by RNA polymerase II (RNAPII) is
a sophisticated process involving numerous factors that
enable regulated progression of the polymerase through
sequential stages of the transcription cycle (1). Therein,
the C-terminal domain (CTD) of the Rbp1 subunit of
RNAPII, consisting of multiple heptapeptide repeats with
consensus sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser, under-
goes a dynamic cycle of post-translational modifications
and cis/trans isomerizations, providing a platform for
mRNA biogenesis and export factors (2). Among vari-
ous modifications, Ser2 phosphorylation (Ser2-P) of the
CTD is most strongly linked to productive transcription
and pre-mRNA processing, the steps following promoter-
proximal pausing of RNAPII (3,4). In addition to the well-
established P-TEFb kinase, which consists of the catalytic
Cdk9 and regulatory cyclin (Cyc) T subunits, recent ev-
idence from fruit fly and human cells indicates that the
Cdk12/CycK complex catalyzes the Ser2-Pmark as well (5–
9). Likewise, Ctk1 and Lsk1, the yeast orthologs of Cdk12,
are major Ser2-P kinases in Saccharomyces cerevisiae and
Schizosaccharomyces pombe, respectively (10,11). Illustrat-
ing the significance of this novel transcriptional kinase,
genetic inactivation of CycK in mice is embryonic lethal
(6), possibly due to the role of Cdk12/CycK in maintain-
ing embryonic stem cell self-renewal (12). In contrast to
the broad requirement for P-TEFb in transcription (13,14),
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depletion of Cdk12/CycK in human cells leaves expres-
sion of most genes unaltered (6). However, a prominent
group among the downregulated genes is the one direct-
ing DNA-damage response (DDR), which includes many
core players that ensure genomic stability, such as BRCA1,
ATR, FANCI and FANCD2. Accordingly, knockdown of
Cdk12/CycK induces DNA damage, as well as sensitivity
to various DNA damaging agents (6). This important func-
tion of Cdk12/CycK seems to be evolutionarily conserved
as mutations of CTK genes in S. cerevisiae prevent upreg-
ulation of several DNA repair genes, rendering yeast cells
incapacitated in the face of genotoxic insult (15,16).
Mutations in factors controlling transcription underlie
many diseases including cancer (17). While contribution
of misregulated transcription elongation to tumorigenesis
through P-TEFb has been documented (13,18,19), the rela-
tionship between mutations in Cdk12/CycK, altered gene
expression and relevance to cancer has not been defined.
Importantly,CDK12 is perturbed in several cancers, includ-
ing breast, gastric and ovarian cancer. In breast cancer,
CDK12 was found to be co-amplified with ERBB2, the ty-
rosine kinase receptor gene, which is deregulated in about
20% of breast tumors (20,21). Furthermore, out-of-frame
rearrangements ofCDK12were identified in micropapillary
breast carcinoma, 13% of ERBB2 positive cancers (22) and
gastric cancers (23). Finally, recent work by The Cancer
Genome Atlas (TCGA) on the high-grade serous ovarian
carcinoma (HGS-OvCa) has provided the most compelling
evidence for a possible role for mutated CDK12 in cancer
(24). Employingwhole-exomeDNAsequencing, the TCGA
study reported a catalog of somatic gene mutations for 316
HGS-OvCa tumor samples. Whereas TP53 dominated the
mutation spectrum, CDK12 was identified as one of only
eight further genes with statistically recurrent somatic mu-
tations. Detailed re-analyses of the CDK12mutations from
the TCGA work and the Catalog of somatic mutations in
cancer (COSMIC) database defined 7 out of 12 mutations
as homozygous, highlighting CDK12 as a novel candidate
tumor suppressor in ovarian carcinoma (25). Importantly,
approximately half of all HGS-OvCa cases display defects
in homologous recombination (HR) (24), the pathway that
repairs DNA double-strand breaks (DSBs) most faithfully
(26). Since depletion of Cdk12/CycK downregulates many
components of DDR that function in HR (27), it is possible
that CDK12mutations in HGS-OvCa could be detrimental
to the efficacy of HR.
Despite the available genetic evidence, the significance
of CDK12 mutations for the assembly and function of
Cdk12/CycK remains to be defined. Furthermore, it is un-
clear how mutations in this novel transcriptional kinase
might influence cancerogenesis. To address these questions,
we focused on CDK12 mutations identified in HGS-OvCa.
Collectively, our results show that theCDK12mutations im-
pair the transcriptional role of Cdk12/CycK in DNA dam-
age repair by HR, elucidating an important link between
the non-functional Cdk12 proteins and cancer.
MATERIALS AND METHODS
Cell culture
HEK 293, HEK 293 Flp-In T-REx (Life Technologies),
Caov-3 (ATCC) and HeLa DR-GFP cell lines were main-
tained in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 100
U/ml penicillin/streptomycin. HCT116 cell line was grown
in DMEM supplemented with 5% FBS. HEK 293 Flp-In
T-REx cell lines expressing 3X-FLAG peptide or Cdk12-
F proteins were generated according to the manufacturer’s
instructions (Life Technologies). All cell lines were main-
tained at 37◦C with 5% CO2. Media and supplements were
from Sigma-Aldrich.
Plasmid DNAs and siRNAs
The plasmids used in this study are listed in Supplementary
Table S4. Rev-Cdk12 and Cdk12-F proteins encoded by
the pRev-Cdk12 and pcDNA3.1-Cdk12-F expression
plasmids, respectively, were described previously (6).
Cdk12 #1 siRNA (sc-44343), CycK siRNA (sc-37600)
and Cdk13 siRNA (sc-72835) were from Santa Cruz
Biotechnology. Cdk12 #2 siRNA has the sense sequence 5′-
rCrArGrArUrGrArCrCrCrUrUrGrArArGrCrUrUdTdT-
3′. Whereas Cdk12 #1 siRNA was used in Figure 5A and
B, and Supplementary Figure S7, Cdk12 #2 siRNA was
used in Figure 5C and Supplementary Figure S8. Control
siRNAs (sc-37007 and SIC001) were from Santa Cruz
Biotechnology and Sigma-Aldrich, respectively. The plas-
mids encoding the wild-type and mutant Cdk12 proteins
that were used to generate the HEK 293 Flp-In T-REx
cell lines were mutated using QuikChange Lightning
Site-Directed Mutagenesis Kit (Agilent Technologies) to
become resistant to Cdk12 #2 siRNA using the following
primer pair: 5′-CAGCAGAACAGACGACACTCGAGG
CTTCAAGCACACCAG-3′; 5′-CTGGTGTGCTTGAA
GCCTCGAGTGTCGTCTGTTCTGCTG-3′.
Immunoprecipitation assay and in vitro kinase assay
HEK 293 Flp-In T-REx cell lines expressing 3X-FLAG
and Cdk12-F proteins upon induction with 1 g/l of
tetracycline for 24 h and transiently transfected HEK
293 cells (Supplementary Figure S2 and Figure 4) were
lysed in buffer C containing 20 mM Tris–HCl (pH.7.9),
150 mM NaCl, 10 mM KCl, 1.5 mM MgCl2, 1 mM
ethylenediaminetetraacetic acid (EDTA), 0.5% NP-40 and
protease/phosphatase inhibitors (Pierce). Upon centrifu-
gation at 20 000 g for 30 min at 4◦C, protein com-
plexes containing Cdk12-F proteins were immuno-purified
from whole cell extracts (WCEs) using 10 l of packed
FLAG-M2 agarose (Sigma-Aldrich) for 1 h at 4◦C. The
immuno-purified complexes were washed 3× with 1 ml of
buffer C, eluted by boiling in Sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) sample
buffer, resolved by SDS-PAGE and examined by Western
blotting using CycK (NBP1-06519, Novus Biologicals) and
FLAG (F3165, Sigma-Aldrich) antibodies. For in vitro ki-
nase assays, immuno-purifications of Cdk12-F-containing
complexes were performed as above with the following
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modifications. Cell pellets were lysed in buffer B containing
50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA,
1% NP-40 and protease/phosphatase inhibitors (Pierce).
The complexes were washed two times with buffer B, fol-
lowed by five washes with the kinase buffer A containing
50 mM Tris–HCl, 100 mM NaCl, 10 mMMgCl2 and 0.1%
NP-40. The beads with the purified complexes were resus-
pended in 30 l of kinase buffer A supplemented with 100
mM adenosine triphosphate, 1 mM dithiothreitol (DTT)
and 300 ng of recombinantGlutatione S-transferase (GST)-
CTD substrate (9) and incubated for 10 min at room tem-
perature, followed by 1 h at 30◦C in Bioermixing blockMB-
102 at 300 rpm. Reactions were stopped by boiling in SDS-
PAGE sample buffer, resolved by SDS-PAGE and analyzed
by Western blotting using CycK (NBP1-06519, Novus Bio-
logicals), Ser2-PRNAPII (ab5095, Abcam), FLAG (F3165,
Sigma-Aldrich) and GST (sc-138, Santa Cruz Biotechnol-
ogy) antibodies.
RNA-tethering gene reporter assay
HEK 293 cells were plated in 12-well format at 100 000 cells
per well and transfectedwith 0.3g of pSLIIB-CATand 1.5
g of Rev-Cdk12, Rev or Cdk12-F expression plasmids as
indicated by the FuGENE6 reagent (Roche)After 48 h, cells
were lysed in 125 l of lysis buffer (250 mMTris–HCl, 0.5%
Triton-X, pH 7.5) for 30 min on ice. Finally, 100 l of the
heat-inactivated cell lysates was supplemented with 50 l of
CAT assay buffer (0.5l of 3H-acetyl CoA (250Ci, Amer-
sham), 30 l of 1.66 mg/ml chloramphenicol, 5 l of 250
mM Tris (pH 7.5), 14.5 l ddH2O) and CAT activity was
measured by a scintillation counter. For normalization, to-
tal protein content inwhole-cell lysatewas determined using
Bio-Rad DC kit. Experiments were done twice in biologi-
cal triplicates. Statistical analysis was performed using one-
way ANOVA. Values are plotted as mean± SD.P-value be-
tween groups is statistically significant (P< 0.05). Levels of
Rev-Cdk12 chimeras were detected by Western blotting us-
ing Cdk12 (sc-32643, Santa Cruz Biotechnology) antibody.
RNAi, RT-qPCR and Western blotting
Thirty to fifty percent confluent Caov-3 or HCT116 cells
were transfected with 10 pmol of control (sc-37007), Cdk12
#1, Cdk12 #2, CycKorCdk13 siRNAusing Lipofectamine
RNAiMax reagent (Life Technologies). Total RNAwas iso-
lated usingRNAzol (MolecularResearchCenter) 72 h post-
transfection. Reverse transcription was performed with M-
MLV reverse transcriptase system using random hexamers
(Life Technologies). For qPCR, 1 l of cDNA was mixed
with 2× Light Cycler 480 Sybr Green Master (Roche) and
0.3 M forward and reverse primer (for sequences of the
primers, see Supplementary Table S5) in a final volume of
20 l. Amplifications were run on the Light Cycler 480II
(Roche) using the following cycle conditions: 94◦C for 2
min (1 cycle); 95◦C for 30 s, 60◦C for 30 s, 72◦C for 30 s
(45 cycles). HPRT expression levels were used for normal-
ization and gene expression differences were calculated us-
ing the threshold cycle method. Values are plotted as mean
± SD. Levels of the analyzed proteins in control, Cdk12,
CycK and Cdk13 siRNA-treated HCT116 cells were deter-
mined by Western blotting using ATM (sc-23921), Chek1
(sc-8408), Rad51D (sc-366363) andGAPDH (sc-32233) an-
tibodies from Santa Cruz Biotechnology.
ChIP-qPCR assay
The assay was performed as described previously (28)
with the following modifications. Hela DR-GFP cells were
plated in 15 cm plates, transfected with 400 pmol of Cdk12
#2 or control siRNA using Lipofectamine RNAiMAX
reagent (Life Technologies) at 70% confluency, plated in two
15 cm plates 24 h later and grown for additional 24 h be-
fore proceeding with the assay. Crude nuclear extract ob-
tained from the confluent 15 cm plate was sonicated in 800
l of RIPA buffer (150 mM NaCl, 1% NP40, 0.5% DOC,
0.1% SDS, 50 mM Tris.Cl pH 8.0, 5 mM EDTA pH 8.0)
10× for 11 s at output power of 11 Watt. Chromatin was
clarified by centrifugation at 13 000 g for 15 min, 400 l
of supernatant added to 12 l of antibody-coupled pro-
tein GDynabeads (Life Technologies) and the mixture sup-
plemented with additional 600 l of RIPA buffer rotated
overnight at 4◦C. Before adding the chromatin, the beads
were pre-blocked with bovine serum albumin and salmon
spermDNAovernight at a final concentration of 0.2g/l,
pre-incubated in 500 l RIPA buffer for 4 h with the anti-
body and collected by magnet to remove the unbound anti-
body.We used 3g of Cdk12 (ab57311), 2g of total/Ser5-
P RNAPII (ab5408) and 1 g of Ser2-P RNAPII (ab5095)
antibodies from Abcam. Normal mouse (sc-2025) and rab-
bit (sc-2027) IgG control antibodies were from Santa Cruz
Biotechnology. Generally, 1/60th of the precipitated ChIP
sample was used for each qPCR reaction. For input DNA,
2.5% of the cleared chromatin was used and 1/100th of
the DNA dissolved in 100 l of water was used for each
qPCR reaction. For sequences of the primers, see Supple-
mentary Table S6. Samples were analyzed by the Strata-
gene Mx3005P real-time polymerase chain reaction system
and FastStart Universal SYBRGreen QPCRMaster (Rox)
(Roche). Results were obtained from three independent ex-
periments. Values are plotted asmean of percentage of input
DNA ± SD.
DR-GFP assay
Hela DR-GFP cells were plated in 6 cm plates at 800
000 and transfected with 100 pmol of control (SIC001) or
Cdk12 #2 siRNAusing Lipofectamine RNAiMAX reagent
(Life Technologies). Twenty-four hours after siRNA trans-
fection, the cells were co-transfected with 2 g of I-SceI
and 3 g of Cdk12-F expression vectors or a parental
pcDNA5/FRT/TO/3XFLAG vector as indicated by us-
ing Lipofectamine 3000 reagent (Life Technologies). Af-
ter 48 h, the cells were trypsinized, collected by centrifu-
gation at 300 x g for 5 min, resuspended in 500 l of
DMEM and analyzed for GFP fluorescence using BD Ac-
curi flow cytometer. Experiments were performed in biolog-
ical triplicates and statistical analysis was done using one-
way ANOVA. The error bars represent the mean ± SD. P-
value between groups is statistically significant (P < 0.05).
Levels of Cdk12-F proteins were detected by Western blot-
ting using Cdk12 (sc-32643, Santa Cruz Biotechnology) an-
tibody.
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Statistical analysis of TCGA study
The expression levels of DDR genes in TCGA were
downloaded from the Oncomine database (TCGA Ovarian
dataset). The information about CDK12 mutation status
was obtained from the COSMIC database. Data from these
repositories was retrieved on February 26, 2014. Samples
for which CDK12 mutation status was not available in
COSMIC were discarded from the TCGA Ovarian dataset
similarly to the five samples ‘variants of unknown origin’
and ‘previously reported’ (1 sample) resulting in 462 HGS-
OvCa samples. Out of these samples, there are 453 CDK12
wild-type samples, four samples with missense mutation in
CDK12 and five samples with nonsense/indel mutation in
CDK12 (see also Supplementary Table S1). Data were ana-
lyzed with the Statistica software (Version 12.0) and visual-
ized usingGraphPadPrism 5.Results are expressed asmean
with standard error of the mean. The Shapiro-Wilk test
was used to assess the normal distribution of the variables
(P > 0.05). Data without a normal distribution were ana-
lyzed with non-parametric test (Mann–Whitney test), and
data with a normal distribution were analyzed with para-
metric test (unpaired t-test). Unpaired t-test with Welsch’s
correctionwas applied for variables with significantly differ-
ent variances (F-test, P< 0.05). The statistical analysis was
conducted at 95% confidence level. Symbols used to express
statistical significance: non-significant (ns) = P > 0.05; * =
P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001.
Structural analyses
Structural analysis of theCDK12mutations was performed
on the human Cdk12/CycK structure determined at 2.2 A˚
resolution (4NST, (9)). Themolecular diagrams were drawn
with PyMOL (http://www.pymol.org/).
RESULTS
Defective interaction between CycK and Cdk12 is the pre-
dominant consequence of CDK12 mutations in HGS-OvCa
In this study, we focused our attention on nine validated
CDK12mutations, whichwere identified in the TCGAwork
(24), including five nonsense and insertion/deletion mu-
tations, as well as four missense mutations (Supplemen-
tary Table S1 and Figure 1A). Among the nonsense muta-
tions, the L122fs4* and Q602* are the most drastic, since
they yield the mutant Cdk12 proteins without most pre-
dicted regions. Next, the nonsense W719* and the insertion
E928fs27* mutation terminate Cdk12 at the start and in the
middle of its kinase domain (KD), respectively. Finally, the
four missense mutations, including R882L, Y901C, K975E
and L996F and an internal deletion T1014 Q1016 mu-
tation are all positioned within the KD of Cdk12. Of
note, by inspecting the COSMIC database, we found that
among the nine HGS-OvCa patient cases with the mutated
CDK12, each sample contains one CDK12 mutation (data
not shown), providing the rationale for examining the im-
pact of single CDK12 mutations.
We analyzed W719* and E928fs27* as the two most rep-
resentative CDK12 nonsense and insertion mutations, as
well as all four CDK12 missense mutations (Figure 1A).
Whereas the deletions of the Cdk12 KD brought about by
the former mutations are expected to inactivate Cdk12, it is
the evolutionary conservation of the amino acids altered by
the latter mutations that likely reflects their functional im-
portance. In fact, except for the K975 residue which is con-
served from fruit flies to humans, the R882, Y901 and L996
residues are all conserved from budding yeast to humans
(Supplementary Figure S1). To get a structural perspective
on these mutations, we took advantage of the crystal struc-
ture of the humanCdk12/CycK complex encompassing the
KD of Cdk12 and the cyclin box domain of CycK (9). An
important characteristic of this structure is that CycK in-
teracts only with the N-terminal lobe of the KD. However,
upon positioning the CDK12 mutations on the structure,
we found that the insertion and missense mutations are all
located within the C-terminal lobe of the KD (Figure 1B).
This observation suggested that possible effects of the mu-
tations on the Cdk12/CycK complex could be exerted via
allosteric mechanisms.
Activation of any Cdk is a two-step process wherein the
binding between the Cdk KD and the cyclin reorients the
catalytic cleft of the kinase, setting the stage for its full acti-
vation by T loop phosphorylation (29,30). Thus, we next
asked whether the CDK12 mutations identified in HGS-
OvCa affect the interaction between Cdk12 and CycK (Fig-
ure 1C). Here, we employed the Flp-In T-REx system to
generate stable HEK 293 cell lines each expressing the wild-
type or mutant 3XFLAG epitope-tagged Cdk12 (Cdk12-F)
proteins upon tetracycline induction. This system allows ac-
curate comparison between the CDK12 mutations because
the integration of individual Cdk12 expression vectors to
the defined locus ensures the same genetic background of
different cell lines. Upon immuno-purifying the wild-type
and mutant Cdk12-F proteins from the WCEs, we exam-
ined the levels of endogenous CycK in these isolations by
Western blotting (Figure 1C, bottom panels). As expected,
the wild-type Cdk12 interacted with CycK, and the mutant
Cdk12 W719* and E928fs27* proteins failed to do so (Fig-
ure 1C, lanes 1–4). In contrast, while the mutant Cdk12
R882L and K975E proteins displayed unperturbed CycK
binding, this interaction was greatly reduced or lost in the
case of the Y901C or L996F mutations, respectively (Fig-
ure 1C, lanes 5–8). We also asked whether the binding be-
tween Cdk12 and CycK is impacted by the panel ofCDK12
mutations found in lung, skin, ovarian, and large intestine
cancers (23,31,32) (Supplementary Figure S2). Of note, a
relative majority of all currently identified CDK12 muta-
tions in human cancers clusters within the KD, while the
rest of them are located within other Cdk12 regions, such as
those with many arginine/serine (RS) residues and proline-
rich motifs (PRM) (Supplementary Table S2). Thus, we se-
lected S325N and S352F as the Cdk12 mutations represent-
ing the RS region, and the G909R and E1024* mutations
found within and right after the Cdk12 KD, respectively.
While the mutations within the RS region did not show any
defects in CycK binding, the mutant Cdk12 G909R protein
lost the ability to bind CycK, and the E1024* mutation de-
creased this interaction considerably (Supplementary Fig-
ure S2B, top panels, lanes 3–6). Collectively, these findings
demonstrate that individual CDK12 mutations in HGS-
OvCa and other cancers that delete or alter theKD can have
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Figure 1. CDK12 mutations in HGS-OvCa abrogate the activity of Cdk12 predominantly by impairing the interaction between Cdk12 and CycK. (A)
Schematic depiction of the wild-type and mutant Cdk12 proteins containing individual CDK12mutations analyzed in this study. Highly structured kinase
domain (KD; red), arginine/serine rich region (RS; green) and two regions with proline-rich motifs (PRM1 and PRM2; blue) are depicted. The ruler on
top indicates the length of Cdk12 protein in amino acids. Vertical lines denote sites of individual missense and insertion mutations. Finally, ‘fs’ stands
for a frame-shift mutation and the associated number indicates the number of altered amino acids at the C-terminus of mutant Cdk12 protein (dotted).
(B) Overall structure of human Cdk12/CycK and positions of the mutations. Cdk12 is shown as cartoon representation in blue and CycK as surface
representation in grey. CDK12 missense, insertion and internal deletion mutations are located in the C-terminal lobe of the KD. The mutated amino acid
residues are highlighted in red. pT893 is highlighted in orange. (C) Effects of the CDK12 mutations on the interaction between Cdk12 and CycK. The
indicated wild-type and mutant FLAG epitope-tagged Cdk12 proteins (Cdk12-F) were immuno-purified from whole cell extracts (WCEs) of the individual
HEK 293 Flp-In T-Rex cell lines using FLAG-M2 agarose (FLAG IP) and examined for their interaction with endogenous CycK. Levels of Cdk12-F and
CycK proteins inWCEs (INPUT, 5% ofWCEs; top) and IPs (FLAG IP; bottom) were detected byWestern blotting using FLAG and CycK antibodies. (D)
CDK12 mutations abrogate the kinase activity of Cdk12. The indicated wild-type and mutant Cdk12-F proteins were immuno-purified (IP) as in panel C
and the complexes were examined for their kinase activity by in vitro kinase assay (IVKA) toward the recombinant GST-CTD. Levels of Ser2-P GST-CTD
isoforms and input GST-CTD (30%) were detected by Western blotting using Ser2-P-specific RNAPII and GST antibodies.
detrimental effects on the formation of the Cdk12/CycK
complex. However, some mutations did not interfere with
the binding between Cdk12 and CycK, the presumed oblig-
atory step in the activation of Cdk12, raising a possibility
that activity of those mutant Cdk12 proteins is not com-
promised.
CDK12 mutations in HGS-OvCa abrogate the kinase activ-
ity of Cdk12
To investigate the effects of the mutations on the catalytic
activity of Cdk12, we next performed in vitro kinase assays.
We immuno-purified the wild-type and mutant Cdk12-F-
containing complexes from WCEs of the HEK 293 Flp-
In cell lines as above and used their comparable amounts
in the kinase assays employing the recombinant GST-CTD
protein as a substrate (Figure 1D and Supplementary Fig-
ure S2C). Since Cdk12/CycK catalyzes the formation of
Ser2-P in human cells (6–8), we followed kinase activity
of the Cdk12-F-containing complexes by Western blotting
using the antibody specific for this RNAPII CTD mark.
Compared with our control immuno-purification, which
was prepared using WCEs of HEK 293 Flp-In cell line ex-
pressing 3XFLAG peptide, the wild-type Cdk12-F protein
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phosphorylated the GST-CTD chimera effectively (Fig-
ure 1D, lanes 1–2). However, except for the mutant Cdk12
K975E protein, the entire set of the proteins containing
the CDK12 mutations failed to phosphorylate the GST-
CTD above background levels (Figure 1D, lanes 3–8). Us-
ing the same experimental approach, we also examined cat-
alytic activity of the panel of Cdk12 proteins carrying the
mutations found in various cancers (Supplementary Figure
S2B). While we observed that the S325N and S352F muta-
tions had no effect, the mutant Cdk12 G909R and E1024*
proteins displayed impaired kinase activity (Supplementary
Figure S2C, bottom panels, lanes 3–6). Thus, except for one,
all the CDK12 mutations that delete or alter the KD of
Cdk12 ablate the activity of the kinase. Whereas deficient
CycK binding correlated completely with the loss of Cdk12
activity, the R882L mutation inactivated the kinase with-
out impairing CycK binding, suggesting that a subsequent
defect prevents activation of this mutant Cdk12 protein.
Insertion and missense CDK12 mutations in HGS-OvCa
likely elicit structural defects that perturb formation and ac-
tivity of the Cdk12/CycK complex
These findings prompted us to analyse why theCDK12mu-
tations provoke such profound effects on the formation and
activity of the Cdk12/CycK complex (Figure 2). Given that
the mutant Cdk12 W719* protein lacks the entire KD, its
failure to bindCycK and phosphorylate the CTD is not sur-
prising. Even though we did not examine them experimen-
tally, the same applies to the rest of the CDK12 nonsense
mutations that generate more drastically truncated Cdk12
L122fs*4 and Q602* proteins. However, we were particu-
larly eager to understand those CDK12mutations in HGS-
OvCa that alter the KD within its C-terminal lobe but still
compromise the ability of Cdk12 to bind CycK or phospho-
rylate the CTD of RNAPII (Figure 2A).
For these analyses, we again employed the structural in-
formation of Cdk12/CycK (9). First, the E928fs27* muta-
tion, which causes the appearance of 27 irregular residues
before reaching the stop codon, truncates Cdk12 in themid-
dle of the C-terminal lobe, most likely resulting in mis-
folding of the remaining part of the KD including the N-
terminal lobe, leading to the observed defects in CycKbind-
ing and kinase activity. Next, the Y901C mutation substi-
tutes the large aromatic residue located in the core of the
C-terminal lobe and beneath the catalytic center of the ki-
nase with a much smaller cysteine residue, creating a ‘void’
in the local environment and prohibiting multiple bonds of
Y901with the residues nearby (Figure 2B). In turn, the rear-
rangements within the C-terminal lobe are likely to follow,
affecting the conformation of the N-terminal lobe and thus
leading to the decreased assembly and activity of this mu-
tant Cdk12/CycK complex. Furthermore, the L996F mu-
tation is located on helix I in the core of the C-terminal
lobe and surrounded by helices E, F and J, forming a
tight four helical bundle (Figure 2C). It is likely that the
spacious aromatic ring of this Cdk12 mutation demolishes
the helical assembly. In turn, this could provoke misfold-
ing of the C- as well as N-terminal lobes, rendering the N-
terminal lobe refractory to CycK binding, thus inactivating
the kinase. In contrast, the R882L mutation did not affect
the binding of CycK to Cdk12 but did result in the inac-
tive kinase, indicating that this mutation precludes the acti-
vation of Cdk12 following CycK binding. In fact, R882 is
one of the three canonical arginine residues in Cdks that are
coordinated upon activation by the phosphorylated thre-
onine 893 (pT893) in the T loop via salt bridges (9,29).
Subsequently, the arginine residues contact other Cdk12
and CycK groups, extending the organizing influence of
the phosphate group, which completes reorganization of the
catalytic cleft and substrate recognition site initiated by the
cyclin binding. Given that the R882L mutation prevents
the contact to pT893, the subsequent series of events may
not ensue, leading to inactive Cdk12 (Figure 2D). Finally,
K975 is located in the exposed region of the C-terminal
lobe, suggesting no structural role for this residue. That the
K975E mutation did not show any effects on CycK bind-
ing and Cdk12 activity but did compromise the function of
Cdk12/CycK in cells (see Figures 3, 4 and 6 below) may
suggest the failure of our biochemical assays to reveal sub-
tle defects of this mutation. Alternatively, K975 could play
a stimulatory role in Cdk12-dependent gene expression via
a mechanism that has yet to be determined.
We also attempted to shed light on how the G909R and
E1024* mutations could lead to the defects in CycK bind-
ing and the activity of Cdk12. We found that the mutated
residues are located within the C-terminal lobe and right
after the end of the KD, respectively (Supplementary Fig-
ure S3). We cannot offer a probable scenario for the effects
of the G909R mutation. The E1024* mutation, however,
truncates the C-terminal extension of the KD that other-
wise promotes the kinase activity of Cdk12 by stabilizing
the conformation of the KD (9). Thus, the E1024* muta-
tion may impair the latter, leading to the decreased CycK
binding and diminished Cdk12 activity. Overall, we con-
clude that theCDK12mutations within the C-terminal lobe
of KD or right after it likely elicit conformational changes
in the KD. In turn, the CycK interacting surface in the N-
terminal lobe is altered, preventing the interaction between
Cdk12 and CycK, and the subsequent activation of the ki-
nase.
CDK12 mutations in HGS-OvCa decrease transcriptional
activation by Cdk12
The Cdk12/CycK complex is a transcriptional kinase,
which can stimulate expression of target genes (33,34). Since
theCDK12mutations led to such pronounced defects in the
biochemical experiments, we next asked whether they also
compromise transcriptional activation byCdk12 (Figure 3).
Here, we employed a classical RNA tethering gene reporter
assay, composed of the chimeric Rev-Cdk12 protein and
the SLIIB-CAT reporter gene, which has been used to fol-
low transcriptional activation by Cdk12 (6) (Figure 3A).
Therein, the interaction between Rev and the SLIIB RNA
element of nascent transcripts tethers the Rev fusion pro-
tein to RNAPII engaged in transcription, resulting in the
activation of the SLIIB-CAT reporter gene (35).
We first determined whether transcriptional activation by
Rev-Cdk12 requires the kinase activity of Cdk12.Hence, we
constructed themutant Cdk12D877N protein, in which the
aspartic residue within the activation segment ‘DFG’ mo-
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Figure 2. Structural analysis of the CDK12mutations. (A) Schematic representation of secondary structure elements within the KD of Cdk12. Canonical
-helices and -strands as well as boundaries of N- and C-terminal lobes are labeled. Positions of the mutated Cdk12 amino acids analyzed in this study
are indicated on top of the schematic. (B) The hydroxyl group of the Y901 aromatic ring mediates a tight hydrogen bond (2.7 A˚) to the carboxyl group of
E928. Interestingly, the tyrosine is closely surrounded by two cysteines, C862 and C924, which could make the Y901C mutation unfavorable. Hydrophobic
contacts of Y901 are formed to I925 and K861, with P934 stabilizing the conformation of E928. (C) L996 resides on helix I. It is surrounded by T1014
and F1019 on helix J, by C922, G923 and L926 of helix F, and M840 and M844 of helix E. The replacement of L996 by the spacious aromatic ring
of a phenylalanine might preclude the tight assembly of the four helical bundle. (D) R882 is part of the canonical arginine network in CDKs that stabilize
the T-loop upon phosphorylation of the critical threonine. Together with R858 of the HRD motif, R882 mediates salt bridges to the phosphate group of
pT893. Its mutation to leucine might prohibit the conformational arrangement of the T loop required for full activation of the kinase.
tif was substituted with asparagine, the mutation which can
generate a kinase-dead form of Cdk (36). Indeed, while the
mutation did not affect the interaction between Cdk12 and
CycK, it did abolish the activity of Cdk12 in vitro (Supple-
mentary Figure S4A, lanes 1–3). Importantly, it also led to a
significant decrease in the ability of the chimeric Rev-Cdk12
D877N protein to activate transcription (Figure 3B, bars 3
and 10), setting the stage for examining the effects of the
CDK12 mutations.
We hypothesized that the CDK12 mutations in HGS-
OvCa, which abrogated the formation of the Cdk12/CycK
complex and/or activity of the kinase, would hamper the
ability of the Rev-Cdk12 chimera to activate the reporter
gene expression effectively. Indeed, the Rev-Cdk12 chimeric
proteins containing all these CDK12 mutations showed
compromised activation of the reporter gene compared to
the activity of the wild-typeRev-Cdk12 chimera (Figure 3B,
bars 3–7 and 9), correlating with our biochemical findings.
The mutant Rev-Cdk12 chimera harboring the K975E mu-
tation, which did not affect CycK binding and activity of
Cdk12, also failed to activate the reporter gene expression
strongly (Figure 3B, bar 8). This result suggests that the
K975E mutation may indeed interfere with an important
event, which is in addition to the kinase activity required
for the transcriptional activation by Cdk12/CycK. Of note,
among the mutant proteins, the Rev-Cdk12 719* chimera
displayed the highest activity (Figure 3B, bar 4). This result
could reflect that functional regions that remained in this
truncated protein, such as the RS region (see below), be-
come more active at stimulating gene expression compared
to the same regions that reside in the context of the full-
length Cdk12 protein.
Using this reporter assay, we also examined transcrip-
tional properties of the mutant Cdk12 proteins carrying
the CDK12 mutations found in other cancers (Supplemen-
tary Figure S4B). Again, all mutant proteins displayed the
decreased activation of the reporter gene (Supplementary
Figure S4B, bars 3–6). Although the activity of the mu-
tant Rev-Cdk12 G909R and E1024* proteins was compro-
mised the most, the S325N and S352F mutations also de-
creased the activity considerably, arguing for a contributing
role for the RS region in the stimulation of gene expression
by Cdk12/CycK. Collectively, these findings demonstrate
thatCDK12mutations found in HGS-OvCa and other can-
cers compromise the ability of Cdk12 to promote gene ex-
pression, raising the possibility of decreased transcription
of Cdk12-dependent target genes in cancer cells.
HGS-OvCa patient samples with CDK12 mutations exhibit
downregulation of genes of the HR repair pathway
In a previous study that used a non-ovarian HeLa cell line
and RNAi approach, the Cdk12/CycK complex has been
found to promote the expression of ∼30 DDR genes (6).
Among these were key effectors in DNA repair mecha-
nisms, including BRCA1, ATR, FANCD2 and FANCI pro-
teins, implicating the Cdk12/CycK complex in the mainte-
nance of genomic stability. However, whether the CDK12
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Figure 3. CDK12 mutations in HGS-OvCa decrease transcriptional acti-
vation by Cdk12. (A) Schematic depiction of the heterologous RNA teth-
ering assay. Plasmid reporter pSLIIB-CAT contains modified HIV1-LTR
promoter in which the apical region of transactivation response RNA el-
ement (TAR) was substituted with 29-nucleotide stem-loop IIB (SLIIB)
subdomain of the HIV-1 Rev response element (RRE), the Rev bind-
ing RNA sequence. The interaction between Rev (pink oval) and SLIIB
within the TAR/SLIIB stem-loop structure at the 5′ end of nascent RNA
tethers the Rev-Cdk12 chimeric protein to RNAPII engaged in transcrip-
tion, resulting in elevated transcription of CAT reporter gene. CTD of the
biggest RNAPII subunit Rbp1 is represented as a tail of RNAPII (yellow),
wherein white circle depicts Ser2 residue to be phosphorylated by Rev-
Cdk12 (dashed arrow) and gold circles depict Ser5 and Ser7 residues in
an already phosphorylated form. Arrow within HIV1-LTR indicates tran-
scription start site. (B) CDK12 HGS-OvCa mutations compromise stimu-
lation of transcription by Rev-Cdk12. HEK 293 cells were co-transfected
with pSLIIB-CAT reporter gene and plasmids encoding the proteins indi-
cated below the graph. Transcriptional activities of Cdk12-F (white bar 1),
Rev (white bar 2), the mutant Rev-Cdk12 chimeras (red bars) and catalyti-
cally dead Rev-Cdk12 D887N chimera (green bar) are represented as CAT
activities relative to the activity of wild-type Rev-Cdk12 chimera (blue
bar), which was set to 100%. Results are presented as the mean± SD. Lev-
els of the Rev-Cdk12 chimeras and endogenous Cdk12 protein are shown
below the graph and were detected by Western blotting using Cdk12 an-
tibody. The top asterisk (*) indicates migration of the endogenous Cdk12
protein and the bottom one indicates the position of an unspecific band
recognized by the Cdk12 antibody, which serves as a loading control.
mutations affectmRNA levels of these and additionalDDR
genes in HGS-OvCa remains an open question. To ad-
dress this issue, we took advantage of the mRNA expres-
sion data sets of the HGS-OvCa patient samples reported
by the TCGA study (24). We compared gene expression lev-
els between the samples that harbor either the wild-type
CDK12 or CDK12 with the nine validated mutations (Fig-
ure 4). Given that defects within the HR pathway occur in
approximately half of all the HGS-OvCa cases (24), and
that several identified Cdk12-dependent DDR genes are re-
quired for HR (37), we hypothesized that the CDK12 mu-
tations in HGS-OvCa may trigger downregulation of genes
of this most faithful DNA repair pathway. Our compari-
son of mRNA levels of genes encoding the known com-
ponents of HR (for the list of thirty eight examined genes,
see Supplementary Table S3) identified six genes, including
ATM,ATR,CHEK1, FANCI,MDC1 andRAD51D,which
were significantly downregulated (P < 0.05) in tumor sam-
ples with mutated CDK12 in comparison to the samples
carrying the wild-type CDK12 (Figure 4A, Supplementary
Figure S5A, and Supplementary Figure S6). Among these,
only ATR and FANCI were defined previously as Cdk12-
dependent (6). To our surprise, we found that expression
of BRCA1, a key effector of HR and a known Cdk12-
dependent gene, as well as of BRCA2, another important
HRplayer, was not affected in theHGS-OvCa samples with
the CDK12 mutations (Figure 4C). Of note, due to the ab-
sence of the array probes for FANCD2 andMMS22L, two
known Cdk12-dependent genes implicated in the HR path-
way, we were unable to determine whether their expression
was compromised by the CDK12 mutations.
In addition to the HR genes, depletion of Cdk12/CycK
led to decreased expression of many other DDR genes (6).
To determine whether this group of genes is also affected
by the CDK12 mutations, we analyzed their mRNA levels
as above (for the list of twenty three examined genes, see
Supplementary Table S3). We found three DDR genes un-
related to HR, includingNEK9,ORC3L and TERF2, to be
significantly downregulated (P < 0.05) in the patient sam-
ples with mutated CDK12 (Figure 4B, Supplementary Fig-
ure S5B, and Supplementary Figure S6).
To confirm that expression of the previously charac-
terized and the new HR genes identified above requires
Cdk12/CycK in human cells of ovarian origin, we lowered
CDK12 mRNA levels by RNAi in the ovarian carcinoma
Caov-3 cell line. Indeed, compared to cells treated with
a non-targeting control short interfering RNA (siRNA),
cells treated with an siRNA specific to CDK12 displayed
decreased expression of BRCA1, FANCI, FANCD2 and
ATR, the HR genes previously characterized as Cdk12-
dependent (6) (Figure 4D). We observed these effects in
the colon cancer HCT116 cell line as well (Supplemen-
tary Figure S7A). Furthermore, mRNA levels of ATM,
CHEK1, MDC1 and RAD51D, the downregulated HR
genes in the HGS-OvCa cases with mutated CDK12 that
have not been previously defined as Cdk12-dependent, also
decreased upon the knockdown of CDK12 in both Caov-3
and HCT116 cell lines (Figure 4E and Supplementary Fig-
ure S7B). Of note, the depletion of Cdk12 andCycK but not
Cdk13, which forms the separate Cdk13/CycK complex,
led to modest but reproducible reduction of ATM, Chek1
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Figure 4. The crucial DDR genes are downregulated in HGS-OvCa patient samples with mutations in CDK12. (A, B and C) Graphs show comparisons
of relative expression levels between the HGS-OvCa samples with the wild-type or mutated CDK12. The identity of genes is indicated on top of each
graph. The data was generated using the following microarray probes: ATM (212672 at), ATR (209903 s at), CHEK1 (205394 at), FANCI (213007 at),
MDC1 (203062 s at),RAD51D (209965 s at),NEK9 (212299 at),ORCL3 (210028 s at),TERF2 (203611 at),BRCA1 (211851 x at),BRCA2 (208368 s at).
Whereas samples with the wild-type CDK12 are plotted as black triangles, those containing individual missense or nonsense/indel CDK12 mutations are
depicted as colored circles or squares, respectively, as indicated by the legend in the top right corner. Results are presented as mean (red line) with standard
error of the mean (SEM) (black whiskers). P-values are given next to red asterisks (*) and the number of asterisks indicates the degree of significance as
follows: * = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001. Panels A and C show genes related to the HR pathway, while other affected DDR genes are shown
in panel B. (D and E) Depletion of Cdk12 decreases the mRNA levels of HR genes in Caov-3 cells. Relative mRNA levels of genes indicated below the bars
were determined by RT-qPCR using total RNA samples isolated from Caov-3 cells treated with the control (blue bars) or Cdk12 #1 siRNA (red bars).
The error bars represent the mean ± SD.
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andRad51Dprotein levels (Supplementary Figure S7C). To
rule out possible off-target effects of the CDK12 siRNA,
we performed RNAi in same cell lines by targeting a differ-
ent region inCDK12. Again, we observed similar defects on
theHRgene expression (Supplementary Figure S8 and data
not shown). Finally, to provide additional evidence that the
downregulation of all HR genes analyzed here is specific
to the Cdk12/CycK complex, we treated Caov-3 cells with
siRNA targeting CCNK and CDK13. Whereas the knock-
down of CCNK, the gene encoding CycK, led to decreased
expression of the HR genes, that of CDK13 did not (Sup-
plementary Figure S8). Together, these analyses provide im-
portant evidence that in HGS-OvCa patient samples, the
CDK12 mutations lead to decreased expression of a subset
ofDDRgenes, particularly those encoding key components
of the HR pathway.Moreover, considering our biochemical
and gene reporter findings, we conclude that the observed
downregulation ofDDRgenes in patient samples is a conse-
quence of the disabled kinase activity of the mutant Cdk12
proteins.
The Cdk12/CycK complex occupies HR genes and promotes
Ser2 phosphorylation of RNAPII
Given our above findings on the stimulatory role of
Cdk12/CycK in the expression of HR genes, it is important
to determine whether these DDR genes are direct targets of
Cdk12/CycK and whether this complex promotes the lev-
els of Ser2-P of RNAPII at them. To address these possibil-
ities, we employed the quantitative chromatin immunopre-
cipitation (ChIP-qPCR) assay to measure the occupancy of
Cdk12, total/Ser5-P RNAPII and Ser2-P RNAPII at se-
lect genes at three different regions: the vicinity of tran-
scription start site (TSS), the interior of the open reading
frame (ORF) and the vicinity of the polyadenylation site
(pA) (Figure 5). We analyzed all four of the newly identified
HR genes, including ATM, CHEK1,MDC1 and RAD51D,
as well as ATR and FANCD2 representing the previously
established Cdk12-dependent genes. To assess whether the
signals at these positions were specific, we used RAD51D
and FANCI intergenic regions which showed minimal dif-
ferences between the occupancy of Cdk12, both forms of
RNAPII and IgG antibody control (Supplementary Figure
S9A). Because of the subsequent functional studies involv-
ing the HR pathway, we performed the ChIP-qPCR assay
using HeLa DR-GFP cell line, a HeLa cell line derivative
containing one copy of the HR substrate, the direct repeat
green fluorescence protein (DR-GFP) cassette (38).
Following confirmation of successful depletion of Cdk12
(Supplementary Figure S9B), we proceeded with the as-
say on control and Cdk12 knockdown cells. As shown
in Figure 5A and Supplementary Figure S9C, Cdk12 is
present at all three regions of the newly identified as well as
the established Cdk12-dependent HR genes. At the novel
set of genes, Cdk12 enrichment over the intergenic region
ranged from 1.9-fold (at ATM pA region) to 6.1-fold (at
CHEK1 pA region) and averaged 3.1-fold (SD = 1.2). Al-
though these levels were not very robust, they were spe-
cific given that the Cdk12 enrichment over IgG was sub-
stantially higher at genes compared to that at the intergenic
region (Figure 5A, compare blue and gray bars). Whereas
the former were from 7.6-fold (at MDC1 TSS region) to
55.7-fold (at RAD51D ORF region) and averaged 15.7-fold
(SD = 13.2), the latter equaled 3.2-fold. Confirming speci-
ficity of the Cdk12 signals, depletion of Cdk12 decreased
the occupancy of Cdk12 at the novel genes by an aver-
age of 44.8% (SD = 14.0), while the levels of Cdk12 at
the intergenic regions were similar (Figure 5A, compare
blue and red bars, and Supplementary Figure S9A). To
find out whether the Cdk12/CycK complex facilitates Ser2
phosphorylation at these genes, we next monitored the oc-
cupancy of total/Ser5-P and Ser2-P forms of RNAPII at
them in control and Cdk12-depleted cells (Figure 5B and
C and Supplementary Figure S9D and E). The knockdown
of Cdk12 reduced the occupancy of total/Ser5-P RNAPII
by an average of 16.4% (SD = 21.3) and primarily at TSSs
of the genes, where the average decrease was 34.1% (SD
= 12.3) (Figure 5B, compare blue and red bars). This ef-
fect may reflect in part the reported ability of Cdk12/CycK
to phosphorylate the CTD of RNAPII at Ser5 in vitro (9).
Importantly, however, decrease in the levels of the Ser2-P
form of RNAPII was much more pronounced, averaging
48.9% (SD= 13.5) (Figure 5C, compare blue and red bars).
In addition, this reduction was evident at all three gene
regions, thus very likely spanning the entire length of the
genes. We conclude that the HR genes are direct targets of
the Cdk12/CycK complex, which is present at them to fa-
cilitate the CTD Ser2 phosphorylation of transcriptionally
engaged RNAPII.
CDK12mutations inHGS-OvCa disable the stimulatory role
of the Cdk12/CycK complex in the repair of DSBs by HR
In light of our demonstration that the absence of functional
Cdk12/CycK leads to coordinated downregulation of crit-
ical HR genes, we finally asked whether the CDK12 muta-
tions disable the repair of DSBs in DNA by HR (Figure 6).
To this end, we employed the DR-GFP assay, a classical
chromosomal DSB repair assay that has been widely used
tomeasure HR in living cells (Figure 6A) (38). The genomic
DR-GFP cassette contains two direct repeats of differen-
tially mutated enhanced green fluorescent protein (EGFP)
genes both of which fail to produce a functional EGFP
protein. Whereas the upstream repeat has been modified to
contain the recognition site for the rare-cutting I-SceI en-
donuclease and an in-frame termination codon, the repeat
that follows is an EGFP fragment truncated at the 3′ end.
Expression of I-SceI leads to a DSB in the upstream repeat,
triggering the repair by HR using the wild-type sequence of
the downstream repeat as a DNA donor, resulting in EGFP
positive cells.
To determine whether the repair of DSB by HR relies on
Cdk12/CycK, we usedRNAi to deplete endogenous Cdk12
in HeLa DR-GFP cells. Next, we transiently expressed the
I-SceI endonuclease in these cells and in those treated with
the non-targeting control siRNA. In agreement with re-
cent reports (39,40), depletion of Cdk12 decreased the fre-
quency of the HR-mediated repair by∼3.5-fold (Figure 6B,
bars 1–3). To find out whether the CDK12 mutations in
HGS-OvCa result in deficient HR-mediated DSB repair,
we next co-expressed the I-SceI endonuclease together with
the Cdk12-siRNA resistant wild-type and mutant Cdk12-F
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Figure 5. Cdk12/CycK is present at the novel HR genes to promote phosphorylation of the CTD of RNAPII at Ser2. (A, B and C) Control (blue bars)
or Cdk12 knockdown HeLa DR-GFP cells (red bars) were subjected to ChIP-qPCR analysis to determine the levels of Cdk12 (panel A), total/Ser5-P
RNAPII (panel B) and Ser2-P RNAPII (panel C) occupancy at RAD51D intergenic region (IR) and three gene-specific regions as indicated below the
graphs. The identity of genes analyzed is indicated on top of each graph. Levels of IgG signals at IR and gene regions are presented as gray bars. Where
these levels were significantly lower than those obtained with specific antibody, the error bars were omitted for simplicity reasons. Results are presented as
percent of input DNA and plotted as the mean ± SD.
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Figure 6. CDK12 mutations in HGS-OvCa abrogate the ability of
Cdk12/CycK to stimulate the repair of DNA double-strand breaks by
HR. (A) Schematic representation of the DR-GFP recombination sub-
strate. The defective EGFP genes of the cassette, separated by 3.7 kb, are
shown (top). The first one (SceGFP) contains an I-SceI endonuclease site
and an in-frame termination codon (white vertical line), while the second
one (iGFP) is an internal EGFP fragment, yielding GFP− cells. The ho-
mologous EGFP sequences are depicted as black rectangles and the non-
repetitive EGFP sequence is depicted as gray rectangle. Induction of DSB
by I-SceI triggers the repair of SceGFP by HR using the iGFP sequence as
a donor DNA, resulting in wild-type EGFP (green rectangle) and GFP+
cells (bottom). (B) The mutant Cdk12 proteins fail to promote the repair
of the DSB by HR. HeLa DR-GFP cells were treated with the control
or Cdk12 #2 siRNA and transfected with the I-SceI expression plasmid
together with plasmids encoding the wild-type (blue bar) or mutant (red
bars) Cdk12-F proteins as indicated below the graph. The HR frequency
for each experimental condition is represented as the frequency relative
to the one reached by the I-SceI expression in the control siRNA-treated
cells, which was set to 100% (green bar). Results are presented as the mean
± SD. Levels of the endogenous Cdk12 and Cdk12-F proteins are shown
below the graph and were detected by Western blotting using Cdk12 an-
tibody. The top asterisk (*) indicates migration of the endogenous Cdk12
protein and the bottom one indicates the position of an unspecific band
recognized by the Cdk12 antibody, which serves as a loading control.
proteins inHeLaDR-GFP cells depleted of the endogenous
Cdk12 protein. Importantly, the wild-type Cdk12-F protein
rescued the EGFP signal by ∼2.3-fold over the diminished
levels provoked by the Cdk12 depletion, reaching 65% of
the HR frequency in cells with endogenous Cdk12/CycK
(Figure 6B, bars 2–4). In contrast, despite their comparable
expression to the wild-type protein, all Cdk12-F proteins
carrying the CDK12 mutations but one failed at increas-
ing the frequency of HR-mediated repair of the DSB (Fig-
ure 6B, bars 5–10). The only exception was Cdk12 carrying
the K975E mutation, which showed an ∼1.4-fold increase
in the HR frequency over the background levels (Figure 6B,
bar 9). Thus, these functional findings correlate completely
with the damaging impacts of the CDK12mutations on the
activity of the Cdk12/CycK complex that we observed in
our gene expression studies. We conclude that the CDK12
mutations found inHGS-OvCa disable the faithful repair of
DSBs by HR, likely contributing to the pervasive instability
of the genome in this cancer.
DISCUSSION
To clarify the relationship between the genetic alterations
in Cdk12 and cancerogenesis, we focused here on the mu-
tations identified in HGS-OvCa. We provide biochemical,
structural, gene expression and functional evidence that
the recurrent somatic mutations in CDK12 are not inert.
Rather, they are loss-of-function mutations that disable the
ability of the Cdk12/CycK complex to promote the expres-
sion and function of genes critical to the HR DNA repair
pathway. Thus, we uncovered an importantmechanism con-
necting the defects in Cdk12/CycK to cancerogenesis, sup-
porting the notion that CDK12 is a potential tumor sup-
pressor that ceases to function in this most deadly form of
ovarian cancer.
Our findings on the mechanism by which CDK12 muta-
tions incapacitate Cdk12/CycK provide new insights into
the deregulation of Cdks in cancer. It is established that
hyperactivation of the cell cycle Cdks enable canceroge-
nesis (41). Mechanistically, the increased kinase activity
stems from overexpression or amplification of the Cdks
or their corresponding cyclins. In addition, the same can
be accomplished by diminished levels of Cdk inhibitors
(CKI) in cancers or by missense mutations within the KD
of Cdks that disrupt CKI binding. Similarly, transcrip-
tional Cdks, including the Cdk8/CycC and Cdk9/CycT
complexes, promote tumorigenesis by elevated kinase ac-
tivity (17). Whereas CDK8 is overexpressed or amplified
in cancers (42), P-TEFb can enable cancerogenesis in con-
cert with the amplified c-Myc oncogene (13), by stimulat-
ing the improper target gene expression within mixed lin-
eage leukemia (MLL) fusion protein complexes (18) or via
the direct upregulation of transcription factors promoting
the epithelial-mesenchymal transition (19). In contrast, we
demonstrate that the CDK12mutations in HGS-OvCa and
other cancers disable the kinase activity of Cdk12. Our re-
sults on the Cdk12 inactivation in ovarian carcinoma are in
perfect agreement with the recent report by Karnitz labora-
tory (40). Importantly, we further disclose that the loss of
the interaction between Cdk12 and CycK is the predom-
inant mechanism underlying this defect. Of note, among
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transcriptional Cdks, Cdk12 and its paralogue Cdk13 are
mutated most heavily in human cancers (data not shown).
We propose that at least with regard to Cdk12, the KDmu-
tations are selected for during the genesis of human cancers
because of their damaging impacts on the Cdk12 activa-
tion process. Further investigations of the non-KD muta-
tions in Cdk12 and of those in other transcriptional Cdks
are needed to understand their mechanisms and contribu-
tions to cancer.
Our results from the gene reporter assay and the mRNA
expression analysis of HGS-OvCa patient samples indicate
that all CDK12 mutations hamper the ability of Cdk12
to promote target gene expression. Importantly, by using
ChIP-qPCR assay, we find that all examined HR genes
are direct targets of Cdk12/CycK, at which this transcrip-
tion elongation-associated kinase facilitates optimal levels
of RNAPII Ser2 phosphorylation. Together, these findings
suggest that rather than through an indirect mechanism,
the CDK12 mutations in HGS-OvCa directly downregu-
late DDR gene expression by precluding the Cdk12/CycK
complex to exert its stimulatory action on transcriptionally
engaged RNAPII at the genes. However, further work is
needed to reveal which steps in the DDR gene expression
fail to operate due to the inactive Cdk12 proteins. Since the
knockdown of Cdk12/CycK lowers the levels of nascent
transcripts of several DDR genes (6), regulates alternative
splicing (43), and interferes with effective 3′-end formation
of model pre-mRNAs (8,44), the mutations could hamper
the synthesis and maturation of DDR gene transcripts. Be-
cause all CDK12 HGS-OvCa mutations except one inac-
tivate Cdk12 activity in vitro, these possible defects could
stem from the poorly phosphorylated Ser2 residues of the
transcribing RNAPII, preventing efficient recruitment of
elongation andRNAprocessing factors (3,4). Alternatively,
the mutations might antagonize the cooperation between
Cdk12/CycK and some of its recently reported interacting
factors (44,45), resulting in the reduction of gene expres-
sion.
A previous report has found that half of the HGS-OvCa
tumor cases display genetic and epigenetic defects in the
components of the HR repair pathway (24). Our findings
on the causal relationship between the CDK12 mutations
and the failure of the HR-mediated DNA repair shed a
new light on the source of the HR defects in this can-
cer. Efficient HR is mediated by several groups of factors
including components of the ATM/ATR signaling path-
way, BRCA1/2 proteins, Fanconi anemia (FA) proteins and
members of the Rad51 protein family (46–49). Our anal-
ysis of the HGS-OvCa patient samples harboring CDK12
mutations demonstrates significant decrease in mRNA lev-
els of several factors from these groups. In particular, the
ATM/ATR signaling pathway, which responds to DNA
damage and transduces signals to downstream effectors
(50), seems to be predominantly compromised. We find
deficient mRNA levels of ATM, ATR, Chek1 and Mdc1
proteins, out of which only ATR was previously charac-
terized as a Cdk12-dependent gene (6). Next, we also re-
veal decreased expression of mRNA for FANCI, an FA
protein that functions in the repair of DNA inter strand
crosslinks (ICLs) togetherwithFANCD2 (51), the factor vi-
tal to efficient HR. Finally, our analysis shows the decrease
in mRNA levels of Rad51D, a paralogue of Rad51 which
plays a role in the assembly and maintenance of the Rad51
nucleoprotein filament, the critical intermediate for strand
invasion during HR (26). Despite the fact that BRCA1,
a known Cdk12-dependent gene (6,39,40), is not affected
by the CDK12 mutations in HGS-OvCa, we speculate that
expression of this crucial HR protein may be diminished
in earlier stages of this cancer containing CDK12 muta-
tions. Importantly, we noted that HGS-OvCa patient sam-
ples contain somatic and/or germline mutations in all of
the Cdk12-dependent HR genes revealed here. Moreover,
by inspecting the COSMIC database, we found that mu-
tations in these HR genes are mutually exclusive with the
CDK12 mutations (data not shown). This also holds true
for the majority of BRCA1 and BRCA2 mutations, which
are absent in 78% of HGS-OvCa cases that contain CDK12
mutations (39). Together, these revelations suggest that mu-
tatingCDK12 equips the developing cancer cells with an al-
ternative source of defects in the HR repair pathway, which
is achieved by the collective downregulation of critical HR
genes. Finally, three recent studies showed that depletion of
Cdk12 sensitizes ovarian cancer cell lines to PARP1/2 in-
hibitors (22,39,40). Because this sensitivity is a hallmark of
the defective HR pathway, our work is in agreement with
these findings and also supports the possibility that tumors
with CDK12mutations might be particularly susceptible to
the therapy with these inhibitors.
Together, our study provides a framework for under-
standing how mutations in Cdk12/CycK could promote
cancerogenesis. By impairing HR, the most error-free cellu-
lar repair mechanism of DSBs,CDK12mutations may elicit
the usage of error-prone DNA repair pathways, including
non-homologous end joining and single-strand annealing
(52). As a result, spontaneous and DNA damage-induced
gene and chromosomal aberrations are likely to accumu-
late, giving rise to the unstable genome, the enabling char-
acteristic of any cancer (53). Because HR plays a central
role in repairing ICLs that stall replication forks (54), an
increase in errors during DNA replication, which is an im-
portant source of genomic instability, can also stem from
the HR deficiency provoked by the CDK12 mutations. In
support of this possibility, depletion of Cdk12/CycK sen-
sitizes cells to the ICL-inducing drug mitomycin C (6), and
CycK is one of the major proteins underlying the resistance
to camptothecin, the drug that creates an obstruction in the
DNA, thereby blocking its replication (55). Finally, unlike
ATM,which is activated byDSBs,ATR responds to a broad
spectrum of DNA aberrations. In addition to DSBs, it is
activated primarily by replication protein A-coated single
stranded DNA, an intermediate in many DNA repair path-
ways, such as nucleotide excision repair, mismatch repair
and base excision repair (50). Thus, we speculate that the
loss-of-function CDK12 mutations may trigger malfunc-
tions in a variety of DNA repair pathways, contributing to
the remarkable genomic disarray in HGS-OvCa.
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